iTeos Therapeutics, Inc.
ITOSDelisted Aug 29, 2025- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001808865
iTeos Therapeutics, Inc. was delisted on Aug 29, 2025; its insiders filed their last Form 4 on Aug 29, 2025; 137 institutions reported holding it in 13F filings for Q2 2025, worth $377.0M in total; no superinvestor held it.
Q3 2022 vs. Q2 2022
How the institutions holding iTeos Therapeutics, Inc. changed between Q2 2022 and Q3 2022.
All holders in Q3 2022All holders in Q2 2022
| Measure | Q2 2022 | Q3 2022 | Change |
|---|---|---|---|
| Holders | 153 | 143 | −10 |
| Shares | 37.1M | 36.6M | −490.8K (−1.3%) |
| Value | $768.1M | $698.2M | −$69.9M (−9.1%) |
New holders (18)
Institutions that held iTeos Therapeutics, Inc. at the end of Q3 2022 but not at the end of Q2 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Jacobs Levy Equity Management, Inc | 466,325 | $8.88M | 0.07% |
| BNP Paribas Arbitrage, SA | 47,064 | $896.6K | 0.00% |
| Virginia Retirement Systems Et Al | 43,000 | $819.1K | 0.01% |
| Prairiewood Capital, LLC | 32,269 | $615.0K | 0.51% |
| Qube Research & Technologies Ltd | 29,242 | $557.0K | 0.00% |
| Public Employees Retirement System of Ohio | 27,049 | $515.0K | 0.00% |
| Jupiter Asset Management Ltd | 22,192 | $423.0K | 0.01% |
| Zebra Capital Management LLC | 12,271 | $234.0K | 0.89% |
| Mirae Asset Global Investments Co., Ltd. | 11,124 | $212.0K | 0.00% |
| Teachers Retirement System of the State of Kentucky | 6,143 | $117.0K | 0.00% |
| Amundi | 1,799 | $35.0K | 0.00% |
| Gladius Capital Management LP | 1,586 | $31.0K | 0.01% |
| Wipfli Financial Advisors LLC, | 372 | $7.00K | 0.00% |
| China Universal Asset Management Co., Ltd. | 333 | $6.00K | 0.00% |
| Allworth Financial LP | 32 | $1.00K | 0.00% |
| Farmers & Merchants Investments Inc | 14 | $0 | 0.00% |
| First Horizon Advisors, Inc. | 35 | $0 | 0.00% |
| Glassman Wealth Services | 9 | $0 | 0.00% |
Sold out (28)
Institutions that held iTeos Therapeutics, Inc. at the end of Q2 2022 and filed for Q3 2022 without it.